Regulatory Approval

Regulatory Approval

Eco Animal Health Group Plc

3 February 2014

ECO Animal Health Group plc

(AIM: EAH)

ECO RECEIVES FURTHER MARKETING AUTHORISATION FOR AIVLOSIN® IN CANADA

ECO is pleased to report that the Veterinary Drugs Directorate (VDD) of Health Canada has granted ECO a marketing authorisation for Aivlosin® 17% premix for the in- feed medication of swine.

This important new marketing authorisation, ECO’s second in Canada, will allow a major expansion of ECO’s potential market in North America. Canada is the ninth largest pork producing country in the world producing about 2 million tons annually.

Aivlosin^® 17% premix will be marketed for the treatment of ileitis (porcine proliferative enteropathy (PPE)), an enteric disease. Together with the first marketing authorisation in Canada , Aivlosin® 625 mg/g Water Soluble Granules for water medication of swine, ECO will now be very well placed for the versatile servicing of the pork producing industry in that country.

Aivlosin®, ECO’s patented macrolide antibiotic, is used for the medication of economically important respiratory and enteric (gut) diseases in pigs and poultry.

Peter Lawrence, Chairman of ECO Animal Health Group, commented “This Canadian market authorisation is a further encouraging step in the ongoing development of Aivlosin^® as a multi-species, versatile brand that treats a multitude of different diseases. It underlines ECO’s commitment to be a major force in the global market for animal health products.”

Contacts:

ECO Animal Health Group plc	Â	Peter Lawrence 020 8336 6190
		Marc Loomes 020 8447 8899
Spiro Financial		Anthony Spiro 020 8336 6196
Cenkos Securities plc (Nominated Adviser)		Stephen Keys 020 7397 8926

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.